Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes

Copping, Roy; Mirzadeh, Saed; Stracener, D. W.; Denton, David; Murphy, Karen E.; Wright, Joseph; Hickman, Eva; Marcus, Chris

doi:10.1016/j.jmir.2019.11.054

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…229 Th can be produced by irradiating 226 Ra with an intense neutron flux, resulting in three successive neutron capture reactions (interspersed by β − decays): 226 Ra( n , γ ) 227 Ra, 227 Ac( n , γ ) 228 Ac, and 228 Th( n , γ ) 229 Th. This production path is being investigated at ORNL's High‐Flux Isotope Reactor (HFIR), with an emphasis on target development and yield measurements . The measured yield of 229 Th was approximately 2.8 MBq per gram of radium and per day of irradiation .…”

Section: Production Of 225acmentioning

confidence: 99%

Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand

Bruchertseifer

Kellerbauer

Malmbeck

et al. 2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer. The use of alpha emitters for cancer therapy has two distinct advantages over conventional therapies. The short range of alpha radiation in human tissue (less than 0.1 mm), corresponding to only a few cell diameters, allows selective killing of targeted cancer cells while sparing surrounding healthy tissue. At the same time, the high energy (several MeV) of alpha radiation and its associated high linear energy transfer leads to highly effective cell kill. Consequently, alpha radiation can destroy cells which otherwise exhibit resistance to treatment with beta or gamma irradiation or chemotherapeutic drugs, and can thus offer a therapeutic option for tumors resistant to conventional therapies. Recent results demonstrating the remarkable therapeutic efficacy of alpha emitters to treat various cancers have underlined the clinical potential of TAT. This paper describes the recent clinical experience with 213Bi and 225Ac. In view of the enormous benefit of targeted cancer treatment with alpha emitters, their production will have to be considerably increased beyond current supply capabilities. Alternative production methods based on the irradiation of uranium, thorium, or radium targets at reactors or accelerator facilities have the potential to meet future demand.

show abstract

Section: Production Of 225acmentioning

confidence: 99%